Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Carbon ion radiotherapy in the treatment of gliomas: a review.

Malouff TD, Peterson JL, Mahajan A, Trifiletti DM.

J Neurooncol. 2019 Nov;145(2):191-199. doi: 10.1007/s11060-019-03303-y. Epub 2019 Sep 30. Review.

PMID:
31571113
2.

Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.

Combs SE, Burkholder I, Edler L, Rieken S, Habermehl D, Jäkel O, Haberer T, Haselmann R, Unterberg A, Wick W, Debus J.

BMC Cancer. 2010 Oct 6;10:533. doi: 10.1186/1471-2407-10-533.

3.
4.

Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.

Lawrie TA, Gillespie D, Dowswell T, Evans J, Erridge S, Vale L, Kernohan A, Grant R.

Cochrane Database Syst Rev. 2019 Aug 5;8:CD013047. doi: 10.1002/14651858.CD013047.pub2.

PMID:
31425631
5.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
6.

Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: explorative hypothesis-generating retrospective analysis.

Combs SE, Bruckner T, Mizoe JE, Kamada T, Tsujii H, Kieser M, Debus J.

Radiother Oncol. 2013 Jul;108(1):132-5. doi: 10.1016/j.radonc.2013.06.026. Epub 2013 Aug 6.

PMID:
23932193
7.

Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial.

Kong L, Gao J, Hu J, Lu R, Yang J, Qiu X, Hu W, Lu JJ.

Cancer Commun (Lond). 2019 Feb 20;39(1):5. doi: 10.1186/s40880-019-0351-2.

8.

Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.

Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T, Nikoghosyan A, Haselmann R, Unterberg A, Wick W, Debus J.

BMC Cancer. 2010 Sep 6;10:478. doi: 10.1186/1471-2407-10-478.

9.

Treatment of meningioma and glioma with protons and carbon ions.

Adeberg S, Harrabi SB, Verma V, Bernhardt D, Grau N, Debus J, Rieken S.

Radiat Oncol. 2017 Dec 1;12(1):193. doi: 10.1186/s13014-017-0924-7. Review.

10.

Overview of clinical experiences on carbon ion radiotherapy at NIRS.

Tsujii H, Mizoe JE, Kamada T, Baba M, Kato S, Kato H, Tsuji H, Yamada S, Yasuda S, Ohno T, Yanagi T, Hasegawa A, Sugawara T, Ezawa H, Kandatsu S, Yoshikawa K, Kishimoto R, Miyamoto T.

Radiother Oncol. 2004 Dec;73 Suppl 2:S41-9.

PMID:
15971308
11.

Radiotherapy for diffuse brainstem glioma in children and young adults.

Hu X, Fang Y, Hui X, Jv Y, You C.

Cochrane Database Syst Rev. 2016 Jun 27;(6):CD010439. doi: 10.1002/14651858.CD010439.pub2. Review.

PMID:
27378212
12.

Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base.

Combs SE, Kessel K, Habermehl D, Haberer T, Jäkel O, Debus J.

Acta Oncol. 2013 Oct;52(7):1504-9. doi: 10.3109/0284186X.2013.818255. Epub 2013 Aug 21.

PMID:
23962241
13.

Stereotactic radiosurgery in the management of intracranial gliomas.

Roberge D, Souhami L.

Technol Cancer Res Treat. 2003 Apr;2(2):117-25. Review.

PMID:
12680792
14.

Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.

Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, Tsuji H, Takakura K; Organizing Committee of the Central Nervous System Tumor Working Group.

Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):390-6. Epub 2007 Apr 24.

PMID:
17459607
15.

Proton and Carbon Ion Therapy of Intracranial Gliomas.

Combs SE.

Prog Neurol Surg. 2018;32:57-65. doi: 10.1159/000469680. Epub 2018 Jul 10. Review.

PMID:
29990974
16.

Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?

Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M.

Strahlenther Onkol. 2004 Jul;180(7):401-7. Review.

PMID:
15241527
17.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
18.

Biopsy versus resection for the management of low-grade gliomas.

Jiang B, Chaichana K, Veeravagu A, Chang SD, Black KL, Patil CG.

Cochrane Database Syst Rev. 2017 Apr 27;4:CD009319. doi: 10.1002/14651858.CD009319.pub3. Review.

19.

Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.

Abrigo JM, Fountain DM, Provenzale JM, Law EK, Kwong JS, Hart MG, Tam WWS.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011551. doi: 10.1002/14651858.CD011551.pub2. Review.

20.

Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.

Kong L, Hu J, Guan X, Gao J, Lu R, Lu JJ.

J Cancer. 2016 Apr 10;7(7):774-83. doi: 10.7150/jca.14399. eCollection 2016.

Supplemental Content

Support Center